RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Clinical trials for RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis study tests whether adding the drug ipatasertib to standard hormone therapy (megestrol acetate) works better than hormone therapy alone for people with recurrent or metastatic endometrioid endometrial cancer. About 96 participants with grade 1 or 2 cancer will receive either…
Matched conditions: RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for recurrent ovarian and endometrial cancers? drug tazemetostat under study
Disease control OngoingThis phase II trial is testing the drug tazemetostat in 62 patients whose ovarian or endometrial cancer has returned after prior treatment. The goal is to see if tazemetostat can shrink tumors or stop them from growing. Participants will receive the drug and be monitored for resp…
Matched conditions: RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy plus chemo shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis phase III trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced (stage III or IV) or recurrent endometrial cancer. About 800 participants received either the combo or chemo alone. The …
Matched conditions: RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis phase II trial tests whether adding ribociclib to a standard two-drug regimen (everolimus and letrozole) works better for people with advanced or recurrent endometrial cancer. About 90 participants will be randomly assigned to receive either the two-drug or three-drug combin…
Matched conditions: RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Virus therapy targets Hard-to-Treat endometrial cancer
Disease control OngoingThis early-stage trial tests a specially modified virus (VSV-hIFNbeta-NIS) given through an IV to people with advanced or recurrent endometrial cancer. The virus is designed to attack cancer cells while leaving healthy cells alone, and it includes a tracer to see where it goes in…
Matched conditions: RECURRENT ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC